Figure 3 | British Journal of Cancer

Figure 3

From: Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

Figure 3

Expression of VEGFR2 by human tumour xenografts. (A) Western blot analysis of VEGFR2 in tumour extracts. The amount of protein analysed for PC3=120 μg, A375P=200 μg, HCT116=180 μg, HT29=200 μg, and HN5=200 μg. (B) Expression of VEGFR2 by human tumour xenografts. FACS analysis of VEGFR2 expression in PC3, SW620, A375P, HN5, HCT116, and HT29 tumours dissociated as single-cell suspensions. The fluorescence profiles of cells treated with VEGFR2 antibody (solid line) and isotype controls (dotted line).

Back to article page